Répertoire de l'Université Alfonso X el Sabio

Somatic Mutation Profiling in the Liquid Biopsy and Clinical Analysis of Hereditary and Familial Pancreatic Cancer Cases Reveals KRAS Negativity and a Longer Overall Survival

Afficher la notice abrégée

APA

Earl, Julie & Barreto, Emma & Castillo, María Encarnación & Fuentes, Raquel & Rodríguez Garrote, Mercedes & Ferreiro, Reyes & Reguera, Pablo & Muñoz, Gloria & Garcia Seisdedos, David & Villalón López, Jorge & Sainz, Bruno & Malats, Nuria & Carrato, Alfredo (2021-03 ) .Somatic Mutation Profiling in the Liquid Biopsy and Clinical Analysis of Hereditary and Familial Pancreatic Cancer Cases Reveals KRAS Negativity and a Longer Overall Survival.

ISO 690

Earl, Julie & Barreto, Emma & Castillo, María Encarnación & Fuentes, Raquel & Rodríguez Garrote, Mercedes & Ferreiro, Reyes & Reguera, Pablo & Muñoz, Gloria & Garcia Seisdedos, David & Villalón López, Jorge & Sainz, Bruno & Malats, Nuria & Carrato, Alfredo. 2021-03 .Somatic Mutation Profiling in the Liquid Biopsy and Clinical Analysis of Hereditary and Familial Pancreatic Cancer Cases Reveals KRAS Negativity and a Longer Overall Survival.

https://hdl.handle.net/20.500.12080/39550
dc.contributor.author Earl, Julie
dc.contributor.author Barreto, Emma
dc.contributor.author Castillo, María Encarnación
dc.contributor.author Fuentes, Raquel
dc.contributor.author Rodríguez Garrote, Mercedes
dc.contributor.author Ferreiro, Reyes
dc.contributor.author Reguera, Pablo
dc.contributor.author Muñoz, Gloria
dc.contributor.author Garcia Seisdedos, David
dc.contributor.author Villalón López, Jorge
dc.contributor.author Sainz, Bruno
dc.contributor.author Malats, Nuria
dc.contributor.author Carrato, Alfredo
dc.date.accessioned 2024-02-07T14:24:02Z
dc.date.available 2024-02-07T14:24:02Z
dc.date.created 2021-03
dc.date.issued 2021-03
dc.identifier.uri https://hdl.handle.net/20.500.12080/39550
dc.description.abstract Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis. KRAS mutations occur in up to 95% of cases and render the tumor resistant to many types of therapy. Therefore, these patients are treated with traditional cytotoxic agents, according to guidelines. The familial or hereditary form of the disease accounts for up to 10¿15% of cases. We hypothesized that hereditary and Familial Pancreatic Cancer cases (H/FPC) have a distinct tumor specific mutation profile due to the presence of pathogenic germline mutations and we used circulating free DNA (cfDNA) in plasma to assess this hypothesis. H/FPC cases were mainly KRAS mutation negative and harbored tumor specific mutations that are potential treatment targets in the clinic. Thus, we conclude that cases with a hereditary or familial background can be treated with newer and more effective agents that may ultimately improve their overall survival. es_ES
dc.format application/pdf es_ES
dc.language eng es_ES
dc.rights CC-BY es_ES
dc.rights.uri http://creativecommons.org/licenses/by/4.0/deed.es es_ES
dc.title Somatic Mutation Profiling in the Liquid Biopsy and Clinical Analysis of Hereditary and Familial Pancreatic Cancer Cases Reveals KRAS Negativity and a Longer Overall Survival es_ES
dc.type info:eu-repo/semantics/article es_ES
dc.rights.accessrights info:eu-repo/semantics/openAccess es_ES
dc.identifier.location N/A es_ES


Fichier(s) constituant ce document

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée

CC-BY Excepté là où spécifié autrement, la license de ce document est décrite en tant que CC-BY

Chercher dans le dépôt


Parcourir

Mon compte

Social Media